The role of the acquired immune response in systemic sclerosis

Agarwal SK, Gourh P, Shete S, Paz G, Divecha D, Reveille JD et al (2009) Association of interleukin 23 receptor polymorphisms with anti-topoisomerase-I positivity and pulmonary hypertension in systemic sclerosis. J Rheumatol 36:2715–2723 Allanore Y, Saad M, Dieude P, Avouac J, Distler JH, Amouyel P et al (2011) Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet 7, e1002091 Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S (2009) Type 17 T helper cells—origins, features and possible roles in rheumatic disease. Nat Rev Rheumatol 5:325–331 Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B et al (2007) Phenotypic and functional features of human Th17 cells. J Exp Med 204:1849–1861 Annunziato F, Romagnani S (2009) Heterogeneity of human effector CD4+ T cells. Arthritis Res Ther 11:257 Antiga E, Quaglino P, Bellandi S, Volpi W, Del Bianco E, Comessatti A et al (2010) Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br J Dermatol 162:1056–1063 Arnett FC, Gourh P, Shete S, Ahn CW, Honey RE, Agarwal SK et al (2010) Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis 69:822–827 Artlett CM, Smith JB, Jimenez SA (1998) Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 338:1186–1191 Atamas SP, Yurovsky VV, Wise R, Wigley FM, Goter Robinson CJ, Henry P et al (1999) Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 42:1168–1178 Baraut J, Grigore EI, Jean-Louis F, Khelifa SH, Durand C, Verrecchia F et al (2014) Peripheral blood regulatory T cells in patients with diffuse systemic sclerosis (SSc) before and after autologous hematopoietic SCT: a pilot study. Bone Marrow Transplant 49:349–354 Bielecki M, Kowal K, Lapinska A, Bernatowicz P, Chyczewski L, Kowal-Bielecka O (2010) Increased production of a proliferation-inducing ligand (APRIL) by peripheral blood mononuclear cells is associated with antitopoisomerase I antibody and more severe disease in systemic sclerosis. J Rheumatol 37:2286–2289 Boin F, De Fanis U, Bartlett SJ, Wigley FM, Rosen A, Casolaro V (2008) T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. Arthritis Rheum 58:1165–1174 Boin F, Wigley FM, Schneck JP, Oelke M, Rosen A (2005) Evaluation of topoisomerase-1-specific CD8+ T-cell response in systemic sclerosis. Ann N Y Acad Sci 1062:137–145 Bossini-Castillo L, Martin JE, Broen J, Gorlova O, Simeon CP, Beretta L et al (2012) A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum Mol Genet 21:926–933 Brembilla NC, Montanari E, Truchetet ME, Raschi E, Meroni P, Chizzolini C (2013) Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. Arthritis Res Ther 15:R151 Broen JC, Dieude P, Vonk MC, Beretta L, Carmona FD, Herrick A et al (2012) Polymorphisms in the interleukin 4, interleukin 13, and corresponding receptor genes are not associated with systemic sclerosis and do not influence gene expression. J Rheumatol 39:112–118 Broen JC, Wolvers-Tettero IL, Geurts-van Bon L, Vonk MC, Coenen MJ, Lafyatis R, et al (2010) Skewed X chromosomal inactivation impacts T regulatory cell function in systemic sclerosis. Ann Rheum Dis 69:2213–16 Burt RK, Oliveira MC, Shah SJ, Moraes DA, Simoes B, Gheorghiade M et al (2013) Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet 381:1116–1124 Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J et al (2011) Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 378:498–506 Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L et al (1999) Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 42:963–970 Chizzolini C, Parel Y, De Luca C, Tyndall A, Akesson A, Scheja A et al (2003) Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum 48:2593–2604 Chizzolini C, Parel Y, Scheja A, Dayer JM (2005) Polarized subsets of human T helper cells induce distinct patterns of chemokine production by normal and systemic sclerosis dermal fibroblasts (abstract). Clin Exp Rheumatol 23:739 Chizzolini C, Rezzonico R, De Luca C, Burger D, Dayer JM (2000) Th2 cell membrane factors in association with IL-4 enhance matrix metalloproteinase-1 (MMP-1) while decreasing MMP-9 production by granulocyte-macrophage colony-stimulating factor-differentiated human monocytes. J Immunol 164:5952–5960 Chizzolini C, Rezzonico R, Ribbens C, Burger D, Wollheim FA, Dayer JM (1998) Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. Arthritis Rheum 41:2039–2047 Del Galdo F, Jimenez SA (2007) T cells expressing allograft inflammatory factor 1 display increased chemotaxis and induce a profibrotic phenotype in normal fibroblasts in vitro. Arthritis Rheum 56:3478–3488 Farge D, Henegar C, Carmagnat M, Daneshpouy M, Marjanovic Z, Rabian C et al (2005) Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis. Arthritis Rheum 52:1555–1563 Fenoglio D, Battaglia F, Parodi A, Stringara S, Negrini S, Panico N et al (2011) Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clin Immunol 139:249–257 Ferrarini M, Steen V, Medsger TA Jr, Whiteside TL (1990) Functional and phenotypic analysis of T lymphocytes cloned from the skin of patients with systemic sclerosis. Clin Exp Immunol 79:346–352 Fleischmajer R, Perlish JS, Reeves JR (1977) Cellular infiltrates in scleroderma skin. Arthritis Rheum 20:975–984 Fleming JN, Nash RA, McLeod DO, Fiorentino DF, Shulman HM, Connolly MK et al (2008) Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS ONE 3, e1452 Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C et al (1996) T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 183:2593–2603 Francois A, Chatelus E, Wachsmann D, Sibilia J, Bahram S, Alsaleh G et al (2013) B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res Ther 15:R168 Francois A, Gombault A, Villeret B, Alsaleh G, Fanny M, Gasse P et al (2015) B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis. J Autoimmun 56:1–11 Fukasawa C, Kawaguchi Y, Harigai M, Sugiura T, Takagi K, Kawamoto M et al (2003) Increased CD40 expression in skin fibroblasts from patients with systemic sclerosis (SSc): role of CD40-CD154 in the phenotype of SSc fibroblasts. Eur J Immunol 33:2792–2800 Fuschiotti P, Larregina AT, Ho J, Feghali-Bostwick C, Medsger TA Jr (2013) Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis. Arthritis Rheum 65:236–246 Fuschiotti P, Medsger TA Jr, Morel PA (2009) Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum 60:1119–1128 Gasse P, Riteau N, Vacher R, Michel ML, Fautrel A, di Padova F et al (2011) IL-1 and IL-23 mediate early IL-17A production in pulmonary inflammation leading to late fibrosis. PLoS ONE 6, e23185 Gerber EE, Gallo EM, Fontana SC, Davis EC, Wigley FM, Huso DL et al (2013) Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature 503:126–130 Gorlova O, Martin JE, Rueda B, Koeleman BP, Ying J, Teruel M et al (2011) Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet 7, e1002178 Gorlova O, Martin JE, Rueda B, Koeleman BP, Ying J, Teruel M et al (2011) Correction: identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet 7:e1002178 Gourh P, Arnett FC, Assassi S, Tan FK, Huang M, Diekman L et al (2009) Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 11:R147 Hoffmann KF, McCarty TC, Segal DH, Chiaramonte M, Hesse M, Davis EM et al (2001) Disease fingerprinting with cDNA microarrays reveals distinct gene expression profiles in lethal type 1 and type 2 cytokine-mediated inflammatory reactions. FASEB J 15:2545–2547 Hu PQ, Hurwitz AA, Oppenheim JJ (2007) Immunization with DNA topoisomerase I induces autoimmune responses but not scleroderma-like pathologies in mice. J Rheumatol 34:2243–2252 Hu PQ, Oppenheim JJ, Medsger TA Jr, Wright TM (2006) T cell lines from systemic sclerosis patients and healthy controls recognize multiple epitopes on DNA topoisomerase I. J Autoimmun 26:258–267 Hugle T, O'Reilly S, Simpson R, Kraaij MD, Bigley V, Collin M et al (2013) Tumor necrosis factor-costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts. Arthritis Rheum 65:481–491 Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM et al (2014) Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343:152–157 Kahari VM, Sandberg M, Kalimo H, Vuorio T, Vuorio E (1988) Identification of fibroblasts responsible for increased collagen production in localized scleroderma by in situ hybridization. J Investig Dermatol 90:664–670 Kawai M, Masuda A, Kuwana M (2008) A CD40-CD154 interaction in tissue fibrosis. Arthritis Rheum 58:3562–3573 Klein S, Kretz CC, Ruland V, Stumpf C, Haust M, Hartschuh W, et al (2010) Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma. Ann Rheum Dis 70:1475–81 Komura K, Fujimoto M, Hasegawa M, Ogawa F, Hara T, Muroi E et al (2008) Increased serum interleukin 23 in patients with systemic sclerosis. J Rheumatol 35:120–125 Komura K, Fujimoto M, Matsushita T, Yanaba K, Kodera M, Kawasuji A et al (2007) Increased serum soluble CD40 levels in patients with systemic sclerosis. J Rheumatol 34:353–358 Komura K, Fujimoto M, Yanaba K, Matsushita T, Matsushita Y, Horikawa M et al (2008) Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse. Ann Rheum Dis 67:867–872 Komura K, Sato S, Hasegawa M, Fujimoto M, Takehara K (2004) Elevated circulating CD40L concentrations in patients with systemic sclerosis. J Rheumatol 31:514–519 Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 cells. Annu Rev Immunol 27:485–517 Kreuter A, Hoxtermann S, Tigges C, Hahn SA, Altmeyer P, Gambichler T (2009) Clonal T-cell populations are frequent in the skin and blood of patients with systemic sclerosis. Br J Dermatol 161:785–790 Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y et al (2000) Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 43:2455–2463 Kuwana M, Feghali CA, Medsger TA Jr, Wright TM (2001) Autoreactive T cells to topoisomerase I in monozygotic twins discordant for systemic sclerosis. Arthritis Rheum 44:1654–1659 Kuwana M, Medsger TA Jr, Wright TM (1995) T cell proliferative response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors. J Clin Invest 96:586–596 Kuwana M, Medsger TA Jr, Wright TM (1997) Highly restricted TCR-alpha beta usage by autoreactive human T cell clones specific for DNA topoisomerase I: recognition of an immunodominant epitope. J Immunol 158:485–491 Lafyatis R, O'Hara C, Feghali-Bostwick CA, Matteson E (2007) B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 56:3167–3168 Le Huu D, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K et al (2013) Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease. Blood 121:3274–3283 Liu X, Gao N, Li M, Xu D, Hou Y, Wang Q et al (2013) Elevated levels of CD4(+)CD25(+)FoxP3(+) T cells in systemic sclerosis patients contribute to the secretion of IL-17 and immunosuppression dysfunction. PLoS ONE 8, e64531 Lonati PA, Brembilla NC, Montanari E, Fontao L, Gabrielli A, Vettori S et al (2014) High IL-17E and low IL-17C dermal expression identifies a fibrosis-specific motif common to morphea and systemic sclerosis. PLoS ONE 9, e105008 MacDonald KG, Dawson NA, Huang Q, Dunne JV, Levings MK, Broady R (2015) Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis. J Allergy Clin Immunol 135:946–55.e9 Mackay F, Browning JL (2002) BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2:465–475 Mathian A, Parizot C, Dorgham K, Trad S, Arnaud L, Larsen M et al (2012) Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. Ann Rheum Dis 71:1227–1234 Matsushita T, Fujimoto M, Hasegawa M, Matsushita Y, Komura K, Ogawa F et al (2007) BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice. J Investig Dermatol 127:2772–2780 Matsushita T, Fujimoto M, Hasegawa M, Tanaka C, Kumada S, Ogawa F et al (2007) Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J Rheumatol 34:2056–2062 Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S (2006) Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 54:192–201 Mavalia C, Scaletti C, Romagnani P, Carossino AM, Pignone A, Emmi L et al (1997) Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 151:1751–1758 Mayes MD, Bossini-Castillo L, Gorlova O, Martin JE, Zhou X, Chen WV et al (2014) Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. Am J Hum Genet 94:47–61 Medsger TA Jr, Ivanco DE, Kardava L, Morel PA, Lucas MR, Fuschiotti P (2011) GATA-3 up-regulation in CD8+ T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production. Arthritis Rheum 63:1738–1747 Meloni F, Solari N, Cavagna L, Morosini M, Montecucco CM, Fietta AM (2009) Frequency of Th1, Th2 and Th17 producing T lymphocytes in bronchoalveolar lavage of patients with systemic sclerosis. Clin Exp Rheumatol 27:765–772 Mi S, Li Z, Yang HZ, Liu H, Wang JP, Ma YG et al (2011) Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms. J Immunol 187:3003–3014 Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A et al (2009) Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30:899–911 Nakashima T, Jinnin M, Yamane K, Honda N, Kajihara I, Makino T et al (2012) Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol 188:3573–3583 Nelson JL, Furst DE, Maloney S, Gooley T, Evans PC, Smith A et al (1998) Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 351:559–562 Ohkura N, Kitagawa Y, Sakaguchi S (2013) Development and maintenance of regulatory T cells. Immunity 38:414–423 Okamoto Y, Hasegawa M, Matsushita T, Hamaguchi Y, Huu DL, Iwakura Y et al (2012) Potential roles of interleukin-17A in the development of skin fibrosis in mice. Arthritis Rheum 64:3726–3735 Oriente A, Fedarko NS, Pacocha SE, Huang SK, Lichtenstein LM, Essayan DM (2000) Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 292:988–994 Oriss TB, Hu PQ, Wright TM (2001) Distinct autoreactive T cell responses to native and fragmented DNA topoisomerase I: influence of APC type and IL-2. J Immunol 166:5456–5463 Parel Y, Aurrand-Lions M, Scheja A, Dayer JM, Roosnek E, Chizzolini C (2007) Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. Arthritis Rheum 56:3459–3467 Postlethwaite AE, Holness MA, Katai H, Raghow R (1992) Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 90:1479–1485 Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P (1992) Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166:255–263 Radstake TR, Gorlova O, Rueda B, Martin JE, Alizadeh BZ, Palomino-Morales R et al (2010) Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 42:426–429 Radstake TR, van Bon L, Broen J, Hussiani A, Hesselstrand R, Wuttge DM et al (2009) The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS ONE 4, e5903 Radstake TR, van Bon L, Broen J, Wenink M, Santegoets K, Deng Y et al (2009) Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression. PLoS ONE 4, e5981 Rands AL, Whyte J, Cox B, Hall ND, McHugh NJ (2000) MHC class II associations with autoantibody and T cell immune responses to the scleroderma autoantigen topoisomerase I. J Autoimmun 15:451–458 Rodriguez-Reyna TS, Furuzawa-Carballeda J, Cabiedes J, Fajardo-Hermosillo LD, Martinez-Reyes C, Diaz-Zamudio M, et al (2011) Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study. Rheumatol Int 32:2653–60 Rosenbloom J, Feldman G, Freundlich B, Jimenez SA (1986) Inhibition of excessive scleroderma fibroblast collagen production by recombinant gamma-interferon. Association with a coordinate decrease in types I and III procollagen messenger RNA levels. Arthritis Rheum 29:851–856 Sakaguchi S, Miyara M, Costantino CM, Hafler DA (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10:490–500 Sakaguchi S, Vignali DA, Rudensky AY, Niec RE, Waldmann H (2013) The plasticity and stability of regulatory T cells. Nat Rev Immunol 13:461–467 Sakkas LI, Xu B, Artlett CM, Lu S, Jimenez SA, Platsoucas CD (2002) Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 168:3649–3659 Sandler NG, Mentink-Kane MM, Cheever AW, Wynn TA (2003) Global gene expression profiles during acute pathogen-induced pulmonary inflammation reveal divergent roles for Th1 and Th2 responses in tissue repair. J Immunol 171:3655–3667 Sato S, Fujimoto M, Hasegawa M, Takehara K (2004) Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 50:1918–1927 Sato S, Hanakawa H, Hasegawa M, Nagaoka T, Hamaguchi Y, Nishijima C et al (2000) Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. J Rheumatol 27:2838–2842 Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K (2000) Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 165:6635–6643 Sato S, Hasegawa M, Takehara K (2001) Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 27:140–146 Scaletti C, Vultaggio A, Bonifacio S, Emmi L, Torricelli F, Maggi E et al (2002) Th2-oriented profile of male offspring T cells present in women with systemic sclerosis and reactive with maternal major histocompatibility complex antigens. Arthritis Rheum 46:445–450 Scharffetter K, Lankat-Buttgereit B, Krieg T (1988) Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Investig 18:9–17 Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L (2010) Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 62:2787–2795 Simonian PL, Roark CL, Wehrmann F, Lanham AK, Diaz del Valle F, Born WK (2009) Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis. J Immunol 182:657–665 Slobodin G, Ahmad MS, Rosner I, Peri R, Rozenbaum M, Kessel A et al (2010) Regulatory T cells (CD4(+)CD25(bright)FoxP3(+)) expansion in systemic sclerosis correlates with disease activity and severity. Cell Immunol 261:77–80 Sondergaard K, Stengaard-Pedersen K, Zachariae H, Heickendorff L, Deleuran M, Deleuran B (1998) Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble interleukin-2 receptors (sIL-2R) in scleroderma skin. Br J Rheumatol 37:304–310 Takeda K, Hatamochi A, Arakawa M, Ueki H (1993) Effects of tumor necrosis factor-alpha on connective tissue metabolism in normal and scleroderma fibroblast cultures. Arch Dermatol Res 284:440–444 Truchetet ME, Brembilla NC, Montanari E, Allanore Y, Chizzolini C (2011) Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther 13:R166 Truchetet ME, Brembilla NC, Montanari E, Chizzolini C (2010) T-cell subsets in scleroderma patients. Expert Rev Dermatol 5:403–415 Truchetet ME, Brembilla NC, Montanari E, Lonati P, Raschi E, Zeni S et al (2013) Interleukin-17A+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement. Arthritis Rheum 65:1347–1356 Tsuchiya N, Kuroki K, Fujimoto M, Murakami Y, Tedder TF, Tokunaga K et al (2004) Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis. Arthritis Rheum 50:4002–4007 Valentini G, Baroni A, Esposito K, Naclerio C, Buommino E, Farzati A et al (2001) Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation. J Clin Immunol 21:210–217 van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J et al (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA : J Am Med Assoc 311:2490–2498 Veeraraghavan S, Renzoni EA, Jeal H, Jones M, Hammer J, Wells AU et al (2004) Mapping of the immunodominant T cell epitopes of the protein topoisomerase I. Ann Rheum Dis 63:982–987 Wang YY, Wang Q, Sun XH, Liu RZ, Shu Y, Kanekura T et al (2014) DNA hypermethylation of the forkhead box protein 3 (FOXP3) promoter in CD4+ T cells of patients with systemic sclerosis. Br J Dermatol 171:39–47 Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A et al (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 100:12319–12324 Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, Cheever AW et al (2010) Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med 207:535–552 Wynn TA (2004) Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 4:583–594 Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214:199–210 Wynn TA (2011) Integrating mechanisms of pulmonary fibrosis. J Exp Med 208:1339–1350 Xing X, Yang J, Yang X, Wei Y, Zhu L, Gao D et al (2013) IL-17A induces endothelial inflammation in systemic sclerosis via the ERK signaling pathway. PLoS ONE 8, e85032 Yang X, Yang J, Xing X, Wan L, Li M (2014) Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction. Arthritis Res Ther 16:R4 Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E, et al (2008) CD19 regulates skin and lung fibrosis via toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 6:1650–63 Yoshizaki A, Yanaba K, Iwata Y, Komura K, Ogawa A, Muroi E et al (2011) Elevated serum interleukin-27 levels in patients with systemic sclerosis: association with T cell, B cell and fibroblast activation. Ann Rheum Dis 70:194–200 Yoshizaki A, Yanaba K, Ogawa A, Asano Y, Kadono T, Sato S (2011) Immunization with DNA topoisomerase I and Freund’s complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum 63:3575–3585 Yurovsky VV, Wigley FM, Wise RA, White B (1996) Skewing of the CD8+ T-cell repertoire in the lungs of patients with systemic sclerosis. Hum Immunol 48:84–97 Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC (2002) Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 168:3088–3098 Zhu J, Yamane H, Paul WE (2010) Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 28:445–489